Vertex Pharmaceuticals, Inc.

Yi Zhou

Chao Lin

Ann Dak-Yee Kwong

Francesco Gerald Salituro

Tiansheng Wang

Paul S Charifson

Francois Maltais

Luc J Farmer

Mark Willem Ledeboer

Huai Gao

Emanuele Perola

John J Court

Upul Keerthi Bandarage

Hongbo Deng

Randy Scott Bethiel

John P Duffy

Brian Ledford

Wenxin Gu

Joseph M Kennedy

Michael P Clark

Ioana Davies

M Woods Wannamaker

Ursula A Germann

Dylan H Jacobs

Min Jiang

Steven Jones

Randal Byrn

Ioana Drutu

Ann Kwong

Tara Lynn Kieffer

Douglas John Bartels

James Daniel Frantz

Judith A Lippke

Nagraj Mani

Randal Bym

Benjamin Shames

Sheila Seepersaud

Eileen Z Zhang

James C Sullivan

Luc Farmer

Woods M Wannamaker

Methods of inhibiting the replication of influenza viruses in a biological sample or patient, of reducing the amount of influenza viruses in a biological sample or patient, and of treating influenza in a patient, comprises administering to said biological sample or patient an effective amount of a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (IA) are as described herein. A compound is represented by Structural Formula (IA) or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (IA) are as described herein. A pharmaceutical composition comprises an effective amount of such a compound or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant or vehicle.

Inhibitors of influenza viruses replication

A method of amplifying an HCV nucleic acid in an HCV infected sample comprises amplifying a segment of a DNA template that is complementary to a genome of HCV RNA from the sample by a two-stage PCR, wherein a first stage PCR employs a first outer primer and a second outer primer, and a second stage PCR employs a first inner primer and a second inner primer. The nucleotide sequence of the first outer primer comprises a nucleotide sequence as set forth in SEQ ID NO: 2; or SEQ ID NO:9, wherein optionally 1, 2 or 3 nucleotides are other nucleotides than those of SEQ ID NO: 9. The nucleotide sequence of the second outer primer comprises a nucleotide sequence set forth in SEQ ID NO: 3 or 4; or a nucleotide sequence as set forth in SEQ ID NO: 10 or 11, wherein optionally 1, 2 or 3 nucleotides are other nucleotides than those of SEQ ID NO: 10 and 11. The nucleotide sequence of the first inner primer comprises a nucleotide sequence as set forth in SEQ ID NO: 5; or SEQ ID NO:12, wherein optionally 1, 2 or 3 nucleotides are other nucleotides than those of SEQ ID NO: 12. The nucleotide sequence of the second inner primer comprises a nucleotide sequence as set forth in SEQ ID NO: 6 or 7; or a nucleotide sequence as set forth in SEQ ID NO: 13 or 14, wherein optionally 1, 2 or 3 nucleotides are other nucleotides than those of SEQ ID NO: 13 and 14.

Methods for amplifying hepatitis C virus nucleic acids

The present invention relates to therapeutic combinations comprising a protease inhibitor and a polymerase inhibitor for the treatment of HCV. The present invention also relates to therapeutic combinations comprising VX-950 and a polymerase inhibitor. Also within the scope of the invention are methods using the therapeutic combinations of the present invention for treating HCV infection or alleviating one or more symptoms thereof in a patient. The present invention also provides kits comprising the combinations of the present invention.

Combination therapy for the treatment of HCV infection

Growing community of inventors

Lexington, MA, United States of America

Yi Zhou